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Abstract
BMI1, a stem cell factor and member of the polycomb group of genes, has been shown to
contribute to growth and chemoresistance of several human malignancies including primary
osteosarcoma (OSA). Naturally occurring OSA in the dog represents a large animal model
of human OSA, however the potential role of BMI1 in canine primary and metastatic OSA
has not been examined. Immunohistochemical staining of canine primary and metastatic
OSA tumors revealed strong nuclear expression of BMI1. An identical staining pattern was
found in both primary and metastatic human OSA tissues. Canine OSA cell lines (Abrams,
Moresco, and D17) expressed high levels of BMI1 compared with canine osteoblasts and
knockdown or inhibition of BMI1 by siRNA or by small molecule BMI1-inhibitor PTC-209
demonstrated a role for BMI1 in canine OSA cell growth and resistance to carboplatin and
doxorubicin chemotherapy. These findings suggest that inhibition of BMI1 in primary or met-
astatic OSAmay improve response to chemotherapy and that the dog may serve as a large
animal model to evaluate such therapy.
Introduction
Human osteosarcoma is a highly aggressive primary tumor of bone. Advances in cytotoxic che-
motherapy and high-dose protocols led to dramatic improvements in survival rates nearly
three decades ago. Unfortunately, the prognosis for patients with metastatic disease remains
poor, and despite intensive ongoing research, there have been few improvements over the past
30 years. While novel therapeutics continue to be developed and explored, identification and
targeting of therapy-resistant tumor cells remains a rational approach to improve current stan-
dard of care.
PLOSONE | DOI:10.1371/journal.pone.0131006 June 25, 2015 1 / 17
a11111
OPEN ACCESS
Citation: Shahi MH, York D, Gandour-Edwards R,
Withers SS, Holt R, Rebhun RB (2015) BMI1 Is
Expressed in Canine Osteosarcoma and Contributes
to Cell Growth and Chemotherapy Resistance. PLoS
ONE 10(6): e0131006. doi:10.1371/journal.
pone.0131006
Editor: Mohammad Saleem, Hormel Institute,
University of Minnesota, UNITED STATES
Received: November 3, 2014
Accepted: May 27, 2015
Published: June 25, 2015
Copyright: © 2015 Shahi et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
contained within the paper.
Funding: This study was supported by the Bernice
Barbour Foundation, the Center for Companion
Animal Health-UC Davis School of Veterinary
Medicine, and NCRR K01 RR031272 (currently
supported by the Office of Research Infrastructure
Programs 8K01OD011111-02). The funders had no
role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
The polycomb group (PcG) proteins have been shown to play a critical role in the develop-
ment and progression of cancer [1] and additionally play an important role in response to
DNA damage [2]. PcG proteins are comprised of two multimeric protein complexes, the poly-
comb repressive complex 1 (PRC1) and the polycomb repressive complex 2 (PRC2). The B
cell-specific Moloney murine leukemia virus integration site 1 (BMI1) is a member of the
PRC1 complex of transcriptional regulators and initially recognized as an oncogenic partner of
c-Myc in lymphomagenesis [3]. BMI1 is crucial for blood-cell development and the self-renew-
able potential of a variety of both normal and cancer stem cells [4], and may also play a role in
cancer progression through regulation of both p16/INK4a and p14/ARF [5, 6].
Recently, others have identified a small molecule inhibitor of BMI1 (PTC-209) that demon-
strates differential cytotoxicity against human colorectal cancer cells while having minimal
cytotoxic effects on human peripheral blood mononuclear cells and hematopoietic stem cells at
similar concentrations [7]. In addition, PTC-209 exhibited an irreversible decrease in the
sphere formation ability of primary colorectal tumors in vitro and tumor formation in vivo fol-
lowing a limited dilution assay, suggesting that inhibition of BMI1 has the potential to target
chemo-resistant cancer-initiating cells.
Recent studies have highlighted a potential role for BMI1 in human OSA growth, migra-
tion, and drug resistance, although the individual contribution of BMI1 on the growth of
human OSA cells has been inconsistent [8–10]. Nevertheless, BMI1 protein expression was
previously reported in 18 out of 32 human OSA samples and expression of BMI1 was subse-
quently found to contribute to increased cell viability, colony formation, and chemoresistance
of human OSA cells in vitro [8]. Furthermore, BMI1 significantly contributed to growth of
human OSA in a xenograft murine model indicating that targeting of BMI1 may prove clini-
cally useful. However, to the authors’ knowledge, expression of BMI1 in metastatic OSA has
not been examined.
Spontaneously arising OSA in the dog represents a powerful model to study the biology and
treatment of human OSA and provides several advantages over mouse models [11–13]. We set
out to determine whether BMI1 was expressed in canine OSA tissues including a subset of
patient-matched primary and metastatic tumors. We observed strong nuclear staining of BMI1
in both primary and metastatic canine OSA. Additional staining of primary and metastatic
human OSA tissues demonstrated an identical staining pattern. We further examined expres-
sion of BMI1 in multiple canine OSA cell lines and found that inhibition of BMI1 significantly
reduced the viability, colony formation, and chemoresistance of canine OSA cells in vitro.
Methods
Immunohistochemistry
Immunohistochemical staining was performed by the UC Davis Comprehensive Cancer Cen-
ter shared resources biorepository laboratory. This study was compliant with federal, State, and
UC Davis regulations (IRB ID #293828–3) as well as ISBER guidelines (International Society
for Biological and Environmental Repositories). Briefly, paraffin sections were deparaffinized
and utilizing standard protocols, stained on an automated DAKO platform. A rabbit monoclo-
nal antibody for BMI1 (6964S Cell Signaling) at 1:200 dilution was applied following by an
anti-rabbit secondary antibody and DAB chromagen. A board certified Anatomic Pathologist
(RGE) examined the sections and scored by the percentage of nuclear positive cells.
Cell lines
Three canine OSA cell lines (Abrams, D17, and Moresco) and three human OSA cell lines
(U2OS, SAOS-2, and LM7) were used in this study. The Abrams and Moresco cell lines were a
BMI1 in Canine Osteosarcoma
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gift from Dr. Douglas Thamm and Colorado State University [14–17]. The D17 cell line is
derived from an osteosarcoma lung metastasis and was purchased from ATCC (Manassas,
VA, Cat# CCL-183) [16, 17]. The U20S, SAOS-2, and LM7 cell lines were obtained from the
MD Anderson Characterized Cell Line Core Facility [18, 19]. All cell lines were grown in Dul-
becco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS)
and 1x penicillin/streptomycin, all from Life Technologies (Invitrogen), and incubated at
37°C in 5% humidified CO2. Canine osteoblast cells (Cn406-05) were purchased from Cell
Application Inc.
Drugs
Doxorubicin (Dox, 2mg/mL, #445–9202) and Carboplatin (Carbo, 10mg/mL, #356–6551) was
supplied by Cardinal Health and purchased through the UCDavis VMTH Pharmacy. PTC-209
(#SML1143) was purchased from Sigma-Aldrich and dissolved in DMSO for a stock concen-
tration of 10mM and stored at -80°C.
BMI1 Transfection with siRNAs
Custom designed Canine BMI1 siRNAs, siRNA-1 and siRNA-2, were made by Life Technolo-
gies and the sequences used for each were as follows: BMI1 siRNA-1 (Catalogue #4399665 ID #
s453495) Sense: 5’ GACCUAAAUUUGUACAGUATT 3’, Antisense: 5’ UACUGUACAAAU
UUAGGUCAA 3’, and BMI1 siRNA 2 (Catalogue #4399665 ID #s453496) Sense:5’ GAAAAU
AGCUAAGACUUUATT 3’, Antisense: 5’ UAAAGUCUUAGCUAUUUUCTA 3’. Silencer
Negative Control No. 1 siRNA was purchased from Life Technologies. All siRNAs were recon-
stituted in sterile water for a stock concentration of 50μM. To first determine the knockdown
efficiency of each BMI1 siRNA, 70,000 Abrams cells were seeded into each well of 6-well plates
with 10% FBS media and allowed to adhere. The media was then changed to DMEM with 2%
FBS and cells were incubated for 24hrs. Treatment specific transfection solutions were made by
combining siRNA with Lipofectamine and further diluted using Opti-MEM I reduced serum
media (Invitrogen). 100nmols of BMI1 or control siRNAs was added to each well and cells
were transfected for 24hrs. After transfection, the media was replaced with fresh 2% FBS media
and cells were incubated for an additional 72hrs prior to RNA and protein extraction.
Protein extraction and western blot
Plated cells were washed three times with ice-cold PBS and then lysed with RIPA buffer
(Thermo-Pierce). Protein lysates were clarified with centrifugation and total protein was quanti-
fied using a BCA Protein Assay (Thermo-Pierce). 20–30μg of protein was then separated using
polyacrylamide gel electrophoresis (PAGE) and transferred to a nitrocellulose membrane.
Membranes were blocked with 5%milk in PBST and incubated with primary antibodies over-
night at 4°C. The primary antibodies used were rabbit anti-BMI1 (1:2000, Cell Signaling
#6964S), mouse anti-p16 (1:800, BD Biosciences #51-1325GR) mouse anti-actin (1:20,000,
Santa Cruz #56459), and rabbit anti-GAPDH (1:3000, Santa Cruz #25778). Membranes were
then washed and incubated with an HRP-conjugated anti-rabbit (Thermo-Pierce Cat# 31464)
or anti-mouse (Thermo-Pierce Cat# 31450) secondary antibody for 2hrs, washed again, then
visualized with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo #34095).
Images were captured and exposure was optimized using Protein Simple FluorChemE (Bio-
Techne, San Jose, CA). Figures were arranged using Adobe Photoshop software (version 11.0.2).
Quantification was performed using ImageJ 1.48v software (NIH, http://imagej.nih.gov/ij).
BMI1 in Canine Osteosarcoma
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Real Time RT PCR (qRT-PCR)
RNA was extracted from cell lines using the RNAeasy Plus Mini Kit (Qiagen #74134) and 2μg
of total RNA was converted to cDNA using the High Capacity RNA-to-cDNA Kit (Applied
Biosystems #4387406). BMI1 expression was measured with the TaqMan Dog BMI1 expres-
sion assay (Applied Biosystems Assay #Cf02663120_m1) using the StepOne Plus Real-Time
RT PCR system (Applied Biosystem). BMI1 expression was normalized to HPRT1 (Applied
Biosystems Assay # Cf02626256_m1) and analysis was performed using the delta delta Ct
(ΔΔCt) method. Statistical analysis was performed using Kruskal-Wallis with Dunn’s multiple
comparisons test.
MTS/MTT cell proliferation assays
MTS assays were used to assess proliferation of Abrams canine OSA cells following BMI1
siRNA-mediated silencing. Transfection with BMI1 and negative control siRNAs were carried
out similarly as described above. Abrams cells were seeded in 96-well plates (7k cells/well),
allowed to adhere, then switched to DMEMmedia with 2% FBS for 24hrs. Cells were then
transfected for 24hrs with negative control and BMI1 siRNA-1 at a concentration of 10nmols
per well. Cell viability was analyzed at 24hr and 48hrs post transfection using an MTS assay.
Briefly, all media was removed and fresh media (DMEM 10%FBS) containing MTS reagent [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]
was added to each well and incubated for 2hrs. Absorbance at 490nm was measured with a
spectrophotometer (Spectramax 190, Molecular Devices LLC). Each group contained 6 wells
and mean absorbance is expressed as a percentage of untreated control cells. Statistical analysis
was performed using student’s two-tailed t-test.
MTT assays were used to assess proliferation of Abrams, D17, and Moresco canine OSA
cells following treatment of PTC-209 alone and in combination with Dox or Carbo. 500 cells
were seeded in 96 well plates with DMEM/10%FBS and allowed to adhere overnight (16–
18hrs). For single treatment PTC-209 experiments, cells were incubated with drug for 72hrs at
final concentrations of 0, 200, 300, 400, 500, and 600nM. For combination treatment experi-
ments, cells were incubated with drug(s) for 72hrs at the following final concentrations: PTC-
209 (0, 100, 200, and 500nM), Dox (0, 3, and 30nM), Carbo (0, 3, and 30μM). Vehicle controls
included DMSO (PTC-209), 0.9% saline (Dox), and water (Carbo). Additional controls
included untreated (UT) cells (no veh or drug) and wells containing media (DMEM/10%FBS)
alone (to assess background absorbance). Briefly, MTT solution was added to each well at a
final conc. of 0.5mg/mL and incubated at 37°C for 4hrs. 200uL of DMSO was added to dissolve
formazin crystals and absorbance was measured at 570nM and 630nM (reference wavelength)
using a spectrophotometer (Spectramax 190, Molecular Devices LLC). 6 wells per group were
used for PTC-209 single treatment experiments, and 4 wells per group were used for combina-
tion treatment experiments, and all experiments were repeated twice. Statistical analysis was
performed using 2-way ANOVA with Tukey’s multiple comparisons test.
Clonogenic assay
For clonogenic assays involving BMI1 siRNA meditated silencing, 500 Abrams cells were
seeded in 6-well plates with DMEMmedia containing 10% FBS for 24hrs. The media was then
changed to DMEM with 2% FBS and transfection solutions containing 15nmols of negative
control or BMI1 siRNA-1 were added to each well. After 24hrs of transfection, the media was
replaced with fresh 2% FBS media and cells were immediately treated with Carbo at 0, 0.5, or
0.75μM final concentrations, or Dox at 0, 2.5, or 5.0nM final concentrations. Cells were incu-
bated with drug treatments for 5 days before fixation and staining. Briefly, cells/plates were
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washed twice with ice cold PBS, fixed for 10 min with ice cold 100% methanol for 10 min,
stained with a solution of 0.5% crystal violet in PBS with 25% methanol for 10 min at room
temperature, followed by a final rinse in DI water and allowed to air dry.
Results
Immunohistochemical analysis of BMI1 expression in human and canine
OSA tissues
BMI1 expression was initially analyzed in 31 primary and 7 metastatic OSA samples from 33
canine patients (Table 1). Canine patients included 12 males and 21 females, with median age
of 9. In this sample set, the radius was the most common site for primary canine OSA, while
the lung was the most common metastatic site. Immunohistochemical staining revealed BMI1
expression in all 31 primary canine OSA samples and 6 out of 7 metastatic samples. For all
BMI1 positive canine samples, staining was observed in at least 85% of the cells within the
tumor sample (Fig 1 and Table 1). Normal canine lymph node served as a positive control.
BMI expression was determined via immunohistochemistry in a human OSA tissue micro-
array containing both primary and metastatic OSA tissues. Human samples included 17 pri-
mary and 10 metastatic OSA samples from 27 patients (Table 2). The patients included 18
males and 9 females with median age of 13. In this sample set, the femur was the most common
site for primary OSAs, while the lung was the most common metastatic site. Immunohisto-
chemical staining revealed BMI1 expression in 14 out of 17 human primary OSA samples and
10 out of 10 metastatic samples. Among those, 14 primary and 8 metastatic samples showed
varying degrees of nuclear staining in 100% of the cells within the sample (Fig 2 and Table 2),
while 2 metastatic samples revealed similar staining in about 50% of observed cells (data not
shown).
BMI1 protein expression is upregulated in human and canine OSA cell
lines
BMI1 protein expression was determined by western blot analysis for 3 human (SAOS-2, U2OS,
and LM7) and 3 canine (Abrams, D17, Moresco) OSA cell lines and 1 normal canine osteoblast
cell line. All OSA cell lines showed relatively high levels of BMI1 protein as compared to the
control canine osteoblast cell line, where only a very weak band was observed (Fig 3).
siRNA-mediated BMI1 Knockdown (KD) results in decreased BMI1 RNA
and protein expression in canine OSA cells
The Abrams OSA cell line was transfected with canine BMI1 siRNAs and relative expression of
BMI1 RNA and protein was assessed 72hrs later. Transfection with canine BMI1 siRNA-1 and
2 resulted in a 37% and 31% decrease in BMI1 RNA expression, respectively (Fig 4A). A statis-
tically significant decrease in RNA expression was observed with siRNA-1 (p<0.05). Western
blot assay revealed similar decreases in BMI1 protein expression when Abrams cells were
treated with BMI1 siRNA-1 (48%) or 2 (43%) as compared to negative control siRNA (Fig 4B).
siRNA-mediated BMI1 Knockdown (KD) results in decreased cell
viability in canine OSA cells
To test the effect of BMI1 KD on OSA cell viability, the Abrams cell line was transfected with
the canine BMI1 siRNA-1 and cell viability was measured using an MTS assay 24 and 48hrs
later. Compared to negative control siRNA, a statistically significant decrease in cell viability
BMI1 in Canine Osteosarcoma
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was observed at 24hrs (p<0.0001) and 48hrs (p<0.01) for those cells transfected with the
BMI1 siRNA-1 (Fig 5).
siRNA-mediated BMI1 knockdown sensitizes OSA cells to
chemotherapy
To test the influence of BMI1 knockdown on drug-mediated cell toxicity, negative siRNA and
BMI1 siRNA-1 treated Abrams OSA cells were exposed to increasing doses of Carbo (0, 0.5,
and 0.75μM) or Dox (0, 2.5, 5.0nM) and evaluated in a clonogenic assay. Fewer colonies were
Table 1. Semiquantitative expression analysis of BMI1 in canine primary andmetastatic OSA.
Case # Age Breed Gender Site Location (primary, met) Diagnosis BMI1% (primary, met)
1 10 Mix MC Proximal humerus Osteosarcoma 90
2 10 Rott FS Distal radius Osteoblastic Osteosarcoma 80
3 11 Lab MC Proximal humerus Osteoblastic Osteosarcoma 100
4 9 Grt Dane FS Distal radius, Lung Chondroblastic Osteosarcoma 100, 100
5 7 Eng Mast FS Distal radius Osteosarcoma 100
6 5 Anatolian Sh MC Distal radius Osteoblastic Osteosarcoma 100
7 10 Greyhound MC Proximal humerus Osteoblastic Osteosarcoma 100
8 11 Germ Sh. FS Proximal radius Osteosarcoma 100
9 9 Lab FS Proximal humerus Telangiectatic Osteosarcoma 100
10 10 Rott FS Proximal tibia Osteosarcoma 100
11 11 GSH Pointer MC Proximal humerus Chondroblastic Osteosarcoma 90
12 9 Lab FS Distal femur Osteoblastic Osteosarcoma 100
13 7 Leonberger FS Distal radius, Lung Osteosarcoma 90, NEG
14 9 Rott FS Distal femur Osteosarcoma 100
15 5 Rhod Ridge M Distal radius Osteosarcoma, Mixed type 100
16 7 Gold Ret FS Distal femur Osteosarcoma 100
17 9 Gold Ret MC Mid ulna Osteosarcoma 90
18 9 Rott MC Distal tibia Osteosarcoma 100
19 7 Mix FS Distal femur Osteoblastic Osteosarcoma 100
20 11 Curly C Ret FS Proximal humerus Osteoblastic Osteosarcoma 90
21 8 Mix FS Distal tibia Osteosarcoma Giant cell type 100
22 7 Rott FS Distal femur Osteosarcoma 100
23 10 Mix MC Proximal tibia, Lung Chondroblastic Osteosarcoma 100, 80
24 7 Gr Pyr FS Distal tibia, Lung Osteosarcoma 100, 100
25 5 Bernese MD MC Distal radius, Lung Osteosarcoma 90, 100
26 11 Germ Sh. FS Distal tibia Osteosarcoma 90
27 6 Rott FS Proximal tibia Fibroblastic Osteosarcoma 90
28 7 Malamute FS Distal radius Osteosarcoma 90
29 8 St. Bern FS Distal tibia Osteosarcoma 90
30 7 Mix FS Distal radius Osteosarcoma 90
31 2 Mix MC Distal radius Fibroblastic Osteosarcoma 90
32 6 Old English FS Lung Metastatic Osteosarcoma 100
33 9 Mix MC Lung Metastatic Osteosarcoma 90
The relative percentage of BMI1 expressing cells was measured in OSA samples derived from 33 canine patients. Following IHC with the anti-BMI1
antibody, cells with visible nuclear staining were scored as positive. MC = male castrated, FS = female spayed, NEG = no staining detected.
doi:10.1371/journal.pone.0131006.t001
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Fig 1. IHC analysis of BMI1 expression in canine lymph node, OSA, and adjacent normal bone.Representative images of BMI1 expression and
corresponding H&E staining in canine normal adjacent bone, normal lymph node, and two canine OSA tissues corresponding to cases 18 and 4 from
Table 1. Nuclear staining was visualized in adjacent normal bone. Canine lymph node demonstrated variable nuclear staining of individual lymphocytes and
served as a positive control. BMI1 staining of canine OSA tissues was also localized to the nucleus and varied in intensity.
doi:10.1371/journal.pone.0131006.g001
BMI1 in Canine Osteosarcoma
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observed in wells where cells were pre-treated with BMI1 siRNA-1 compared to cells pre-
treated with negative siRNA and a similar, dose dependent effect was observed for both car-
boplatin and doxorubicin (Fig 6). Pretreatment with BMI1 siRNA followed by carboplatin or
doxorubicin treatment resulted in lower colony formation as compared to either treatment
alone.
PTC-209 decreases BMI1 and increases p16 protein expression in
canine OSA cell lines
Canine OSA cell lines were treated with PTC-209 (100, 200, or 500nM) for 24hrs and BMI1
expression was analyzed in a western blot assay (Fig 7). Compared to vehicle control, BMI1
protein expression decreased by 40% and 25% in the Abrams and D17 cell lines, respectively,
following 500nM PTC-209 treatment. In the Moresco cell line, BMI1 protein expression
decreased by 16% and 39% following 200nM and 500nM PTC-209 treatment, respectively, as
compared to vehicle control. To assess changes in p16 protein expression, canine OSA cell
Table 2. Semiquantitative expression analysis of BMI1 in human primary andmetastatic OSA.
Case # Age Gender Site Location Diagnosis BMI1%
1 80 M Hip Osteosarcoma 100
2 13 F Femur Osteosarcoma 100
3 13 F Humerus Osteogenic Osteosarcoma 100
4 55 M Femur Osteosarcoma 100
5 13 F Right Distal Femur Osteoblastic Osteosarcoma 100
6 62 M Left Femur Osteosarcoma 100
7 13 M Left Ulna Osteosarcoma NEG
8 13 M Left forearm Osteosarcoma 100
9 14 M Left Tibia Osteosarcoma 100
10 13 F Right Distal Femur Osteosarcoma 100
11 21 M S1 Nerve Root Chondroblastic Osteosarcoma 100
12 21 M Right Distal Femur Osteosarcoma 100
13 37 M Tibia Chondroblastic Osteosarcoma NEG
14 59 F Hip Chrondroblastic Osteosarcoma 100
15 26 M Femur Osteosarcoma NEG
16 11 F Femur Osteosarcoma 100
17 11 F Femur Osteosarcoma 100
18 11 F Lung Metastatic Osteosarcoma 100
19 23 M Lung Metastatic Osteosarcoma 100
20 22 M Lung Metastatic Osteosarcoma 100
21 14 M Left Upper Lung Metastatic Osteosarcoma 100
22 11 M Right Chest Mass Metastatic Osteosarcoma 100
23 10 M Right Lower Lobe Lung Metastatic Osteosarcoma 100
24 10 M Right Lower Lobe Lung Metastatic Osteosarcoma 50
25 21 M Left Lung Metastatic Osteosarcoma 50
26 65 M Left Lower Lung Lobe Metastatic Osteosarcoma 100
27 11 F Left Pleural Lining Metastatic Osteosarcoma 100
The relative percentage of BMI1 expressing cells was measured in human OSA samples Following IHC with the anti-BMI1 antibody, cells with visible
nuclear staining were scored as positive. NEG = no staining detected.
doi:10.1371/journal.pone.0131006.t002
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lines were treated with similar doses of PTC-209 for 48hrs and analyzed with western blot (Fig
7). Increases in p16 protein levels could be observed in all cell lines beginning at 100nM PTC-
209 and were highest at the 500nM PTC-209 dose for Abrams (120% increase) and Moresco
(200% increase), but appeared to top out at 200nM for the D17 cell line (54% increase).
Fig 2. IHC analysis of BMI1 expression in human OSA. Representative images of BMI1 expression and
corresponding H&E staining in human OSA tissue microarray samples corresponding to cases 4, 17, and 26
from Table 2. Similar to canine tissues, BMI1 staining of human OSA tissues was intense and localized to the
nucleus.
doi:10.1371/journal.pone.0131006.g002
BMI1 in Canine Osteosarcoma
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BMI1 inhibitor PTC-209 decreases cell viability in canine OSA cell lines
AnMTT assay was used to assess the viability of canine OSA cell lines following 72hrs of expo-
sure to PTC-209. Significant decreases in cell viability were observed beginning at 300nM
PTC-209 with the Abrams (P< 0.01) and Moresco (p< 0.001) cell lines and at 400nM PTC-
209 with the D17 (p< 0.01) cell line (Fig 8). No significant differences were observed between
groups treated with 500 and 600nM PTC-209, where cell viability decreased by 36%, 64%, and
80% for the D17, Abrams, and Moresco cell lines, respectively.
Combination treatment with Dox or Carbo and BMI1 inhibitor PTC-209
Canine OSA cell lines were exposed to varying doses of Dox or Carbo in combination with
PTC-209 and cell viability was measured using an MTT assay. None of the cell lines treated
with the lower doses of Dox (3nM) or Carbo (3μM) in combination with PTC-209 showed a
significant decrease in cell viability as compared to dose matched single treatment PTC-209
(Fig 9). Differences observed between the D17 groups treated with 3nM Dox + PTC-209 (veh,
200, 300nM) and dose matched single treatment PTC-209 are attributed solely to the low dose
Fig 3. Protein expression of BMI1 in human and canine OSA cell lines.Western blot analysis of canine
and human OSA cell lines revealed high expression of BMI1 relative to the normal canine osteoblasts (CO).
Due to close proximity and strong signals for both BMI1 and Actin, two identical gels were loaded and protein
electrophoresis and transfer were performed in parallel. Separate membranes were then probed with
antibodies against BMI1 and Actin as shown. Abrm = Abrams, Mor = Moresco.
doi:10.1371/journal.pone.0131006.g003
Fig 4. Expression of BMI1 mRNA and protein following siRNA knockdown in canine Abrams OSA cells. (A) Fold increase in mRNA expression in Neg
siRNA, BMI1 siRNA-1, and BMI1 siRNA-2 transfected samples relative to untreated samples. Compared to the negative control siRNA, both BMI1 siRNA-1
and siRNA-2 show a trend for decreased BMI1 mRNA expression, although only the BMI1 siRNA-1 treated samples showed statistical significance. Error
bars represent SD and statistical analysis was performed using Kruskal-Wallis with Dunn’s multiple comparisons test. *p<0.05 (B) Similarly, Western Blot
Analysis confirmed that both siRNA-1 and siRNA-2 transfected cells expressed lower levels of BMI1 protein when compared to the Neg siRNA treated cells.
BMI1 band densities were calculated, normalized to GAPDH, and displayed as a percent change in expression relative to Neg siRNA control.
doi:10.1371/journal.pone.0131006.g004
BMI1 in Canine Osteosarcoma
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Dox treatment and no difference was observed between the two groups when exposed to
500nM PTC-209 (Fig 9C).
When the Abrams cell line was treated with PTC-209 in combination with 30nM Dox, a sig-
nificant decrease in cell viability was observed at 300 and 500nM PTC-209, compared to Dox
alone, which were also significantly different from matched single treatment PTC-209 at
300nM (p< 0.0001) and 500nM (p< 0.001), respectively (Fig 9A). Likewise, when combined
with 30μMCarbo, a significant decrease in cell viability was observed at 300 and 500nM PTC-
209, compared to Carbo alone, which were also significantly different from their matched sin-
gle treatment PTC-209 at 300nM (p< 0.0001) and 500nM (p< 0.001), respectively (Fig 9B).
Similarly, when the Moresco cell line was treated with PTC-209 in combination with 30nM
Dox, a significant decrease in cell viability was observed at 200, 300, and 500nM PTC-209,
compared to Dox alone, which were also significantly different from their matched single treat-
ment PTC-209 group (p< 0.0001 for all, Fig 9E). Likewise, when combined with 30μMCarbo,
a significant decrease in cell viability was observed at 300 and 500nM PTC-209, compared to
Carbo alone, which were also significantly different from their matched single treatment PTC-
209 at 300nM (p< 0.0001) and 500nM (p< 0.01), respectively (Fig 9F).
When the D17 cell line was treated with PTC-209 in combination with 30nM Dox, no sig-
nificant decrease in cell viability was observed at any dose of PTC-209, as compared to Dox
alone (Fig 9C). When combined with 30μMCarbo, however, a significant decrease was
observed at 500nM PTC-209, compared to Carbo alone, which was also significantly different
from matched single treatment PTC-209 at 500nM (p< 0.001, Fig 9D).
Discussion
BMI1 has recently been shown to be upregulated in a variety of human cancers, including
brain, breast, prostate, colon, and OSA [8, 20]. To our knowledge, only one study examining
lymphoma cells has evaluated BMI1 expression in canine tumors [21]. Here we report that
BMI1 is highly expressed in canine OSA, similar to what has been reported in human OSA
Fig 5. Effect of BMI1 siRNA transfection on cell viability in AbramsOSA cells.MTS assay showing
decreased cell viability in Abrams canine OSA cells 24 and 48hrs after transfection with Neg siRNA and BMI1
siRNA-1. Absorbance data is shown as a percent of untreated (UT) control cells. Statistical analysis was
performed using student’s t-test. ** p<0.01, **** p<0.0001.
doi:10.1371/journal.pone.0131006.g005
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tissues [8, 10]. In addition, we report for the first time that elevated BMI1 expression is main-
tained in both human and canine OSA metastases. Furthermore, canine OSA cell lines were
found to express high levels of BMI1 protein, and siRNA mediated BMI1 knockdown or small
molecule BMI1 inhibition in canine OSA cells results in a reduction in cellular proliferation
and an increased sensitivity to the chemotherapeutic drugs carboplatin and doxorubicin.
We report positive BMI1 expression in 82% (14/17) human osteosarcoma samples analyzed,
which is higher than the 56% reported previously [8]. Although it is possible that these differ-
ences represent real variability of BMI1 expression between sample sets, it is also possible that
this discrepancy in reported expression results from the dissimilar BMI1 antibodies and spe-
cific criterion used to determine positive BMI1 expression. Of note are distinct differences in
Fig 6. Effects of BMI1 siRNA transfection combined with chemotherapy on colony formation of
AbramsOSA cells. BMI1 siRNA-1 transfection resulted in decreased colony formation when compared with
Neg siRNA treated cells. The addition of Carboplatin (Carbo) or Doxorubicin (Dox) treatment to BMI1 siRNA-
1 transfected Abrams cells resulted in decreased colony formation and growth compared to identically treated
Negative siRNA transfected Abrams cells.
doi:10.1371/journal.pone.0131006.g006
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IHC staining patterns observed between these 2 studies. In the previous report, BMI1 IHC
staining was observed as being both nuclear and cytoplasmic, while the BMI1 staining observed
in our study was almost exclusively nuclear. This is important because the presence of cyto-
plasmic staining observed in the previous report was a defining factor for scoring a sample as
positive for BMI1 expression. While small, a different study previously reported that 3 out of 3
human OSA samples expressed BMI1 protein that was exclusively localized in the nucleus of
OSA cells [10]. What is unknown, however, is whether the specific localization of BMI1 as
cytoplasmic versus nuclear significantly influences the development or progression of OSA as
has been shown in other cancers [22].
Fig 7. Effect of PTC-209 on BMI1 and p16 protein expression in canine OSA cell lines.Western blot showing decreased BMI1 protein expression and
increased p16 protein expression in Abrams, D17, and Moresco canine OSA cell lines after 24hrs (BMI1) and 48hrs (p16) of PTC-209 treatment. Protein
band densities were calculated for each sample, values were normalized to actin, and then shown as a percent change in expression relative to vehicle
control.
doi:10.1371/journal.pone.0131006.g007
Fig 8. Effect of PTC-209 treatment on viability of canine OSA cell lines.MTT assay showing dose
dependent decreases in cell viability following 72hrs of PTC-209 treatment. Absorbance data is shown as a
percent of untreated (UT) control cells. Error bars reflect SD and statistical analysis was performed using
2-way ANOVA with Tukey’s multiple comparisons test. p-values reflect significance as compared to vehicle
control.** p<0.01, **** p<0.0001.
doi:10.1371/journal.pone.0131006.g008
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Fig 9. Effect of combined chemotherapy and PTC-209 treatment on viability of canine OSA cell lines.MTT assay following 72hrs of combined
treatment with doxorubicin (Dox) or carboplatin (Carbo) with PTC-209. (A) Abrams treated with Dox and PTC-209. (B) Abrams treated with Carbo and PTC-
209. (C) D17 treated with Dox and PTC-209. (D) D17 treated with Carbo and PTC-209. (E) Moresco treated with Dox and PTC-209. (F) Moresco treated with
Carbo and PTC-209. Absorbance data is shown as a percent of untreated (UT) control cells. Error bars reflect SD and statistical analysis was performed
using 2-way ANOVA with Tukey’s multiple comparisons test. p-values reflect significance as compared to PTC-209 vehicle control within each dose of Dox or
Carbo. *p< 0.05, ** p<0.01, **** p<0.0001.
doi:10.1371/journal.pone.0131006.g009
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The small molecule BMI1 inhibitor PTC-209 has been shown to decrease BMI protein
expression and induce cytotoxicity in human colorectal cancer cells, but its effects on canine
cancer cells or OSA cells has not previously been evaluated. We observed a decrease in BMI1
protein expression in all three canine OSA cell lines following treatment of PTC-209 at 500nM,
which is consistent with previous reports using human tumor cell lines [7]. Furthermore, it has
known that BMI1 negatively regulates expression of p16/INK4A [6], and as such, we observed
an increase in p16 protein expression in all three canine OSA cell lines following PTC-209 inhi-
bition of BMI1. Others have shown that p16 expression predicts the clinical response to che-
motherapy in human OSA patients [23], which is in alignment with our findings and lends
support to the notion that targeting BMI-1 may enhance response to chemotherapy in clinical
OSA patients.
We found that siRNA-mediated knockdown of BMI1 in Abrams cells and BMI1 inhibition
by PTC-209 in all three canine OSA cell lines (Abrams, D17, Moresco) decreased cell prolifera-
tion in vitro based on colorimetric viability assays. While these findings agree with studies
examining human SAOS-2 OSA cells [8], no such growth inhibition was attributed solely to
BMI1 expression knockdown in the human OSA cell lines 143B or HOS [10]. It is possible that
the methods used, specifically the use of knockdown models, may have given discordant
results, or perhaps that contribution of BMI1 to cellular proliferation may be variable between
cell lines. Indeed, we did observe significant differences in response to BMI1 inhibition between
the three canine OSA cell lines, with respect to both BMI1 protein expression changes and
cytotoxicity. The cell line that appeared to be the most resistant to the cytotoxic effects of BMI1
inhibition (D17, Fig 8), also showed the smallest decrease in BMI1 protein expression following
treatment (Fig 7). Conversely, the cell line that showed the least resistance to the cytotoxic
effects of BMI1 inhibition (Moresco, Fig 8), also showed the largest decrease in BMI1 protein
expression following treatment (Fig 7). D17 also appeared to express the highest level of base-
line BMI1 protein, compared to Abrams and Moresco, which may have contributed to its resis-
tance to PTC-209 (Figs 3 and 7).
All three canine OSA cell lines showed significantly decreased cell viability following combi-
nation PTC-209 treatment and Dox or Carbo, except for D17 which showed significant differ-
ences with PTC-209 combined with Carbo, but not Dox. Our finding that BMI1 appears to
contribute to chemoresistance in canine OSA cells is consistent with previous studies examin-
ing human OSA [8, 9] and other tumor cell lines [24, 25]. We specifically chose to evaluate the
role of BMI1 in chemoresistance to carboplatin and doxorubicin as they represent standard of
care in the management of canine OSA [26, 27].
It has long been known that tumors consist of heterogeneous cell populations in regard to
growth and metastasis [28, 29]. Several studies have suggested that within the heterogenous
tumor cell population, a subset of OSA cells with stem cell characteristics (cancer stem cells or
CSCs) may be responsible for tumor growth and treatment resistance [30, 31]. A recent semi-
nal study by Tomasetti and Vogelstein [32] supports the role of stem cell involvement in cancer
showing a direct positive correlation between the number of stem cell divisions in the lifetime
of a given tissue and the lifetime risk of cancer developing in that tissue. Although evidence
exists that BMI1 is involved in CSC self-renewal and tumorigenesis in other malignancies [20],
it has not been specifically evaluated in putative OSA CSCs. While BMI1 has not been specifi-
cally evaluated as a putative CSC marker in OSA, our findings that BMI1 is highly expressed in
metastases and contributes to chemotherapy resistance may implicate an important role for
BMI1 in OSA CSCs. As such, additional studies aimed at evaluating the potential CSC proper-
ties of BMI1 positive OSA subpopulations may be warranted.
In conclusion, we demonstrate that BMI1 is highly expressed in canine and human primary
and metastatic OSA and that, similar to what has been reported in human OSA cells, selective
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downregulation of BMI1 can sensitize canine OSA cells to the effects of chemotherapy. These
results implicate a role for BMI1 in putative OSA CSCs and establish yet another similarity
between the human and canine disease. Finally, these results demonstrate that targeting of
BMI1 in OSA metastases may represent one approach to improve response to standard of care
cytotoxic chemotherapy.
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